Appendix 4E and Annual Report

Aug 18, 2026 at 9:33 PM EDT · Issued by Percheron Therapeutics Limited via ASX

Filed with ASX · Aug 18, 2026 at 9:33 PM EDT

On 6ix: 6ix.com/news/appendix-4e-and-annual-report-234

Level 30, 35 Collins Street, Melbourne VIC 3000 T: + 61 (0)3 9827 8999 F: + 61 (0)3 9859 7701 www.PercheronTx.com annual report FY2026 b / 2026 ANNUAL REPORT Percheron Therapeutics Limited (ASX: PER) 1. Company details Name of entity: Percheron Therapeutics Limited ABN: 41 095...

View Attachment

6ix hasn’t read this filing yet.

Percheron Therapeutics Limited on 6ix

Earlier from Percheron Therapeutics

Application for quotation of securities - PERAug 14
Notice of date of AGM and other relevant datesAug 11
Percheron Therapeutics Announces CEO SuccessionAug 9
Quarterly Activities Report and Appendix 4CJul 30
Results of Entitlement OfferApr 14

Later from Percheron Therapeutics

Appendix 4G and Corporate Governance StatementAug 18
Vanderbilt Health to conduct clinical trial of HMBD-002Aug 27
Trading HaltAug 27
Percheron receives $0.70m R&D Tax Incentive RebateAug 30
Notification of cessation of securities - PERAug 31

All Percheron Therapeutics news releases

Follow Percheron Therapeutics into a list and get an email when it puts out news.

Follow Percheron Therapeutics